Rozšířená studie pro pacienty dříve zařazené do studií s pelabresibem
Otevřená, multicentrická, rozšiřující studie pro pacienty dříve zařazené do studií s Pelabresibem
The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients).
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
The study will collect and monitor ongoing efficacy information with regard to disease and survival status, as well as safety information with regard to AEs, including SAEs and AEs of special interest (AESI).
Patients are eligible to continue pelabresib treatment as long as the regimen is tolerated, and the patient does not meet any of the discontinuation criteria.
Patients who have previously received pelabresib alone or pelabresib in combination with ruxolitinib or ruxolitinib alone will continue to receive the same regimen as administered in the parent study.
There will be an eligibility check period of up to 28 days for this extension study. Patients who fulfill the inclusion and exclusion criteria are eligible for the study. After the patient willingly provides consent, eligibility will be assessed by the investigator and treatment with pelabresib can be started at the same dose and dosing schedule that was applied in the parent study in the last cycle prior to EOT unless there is need for dose adjustment due to toxicity.
A patient is considered to have completed the study after completion of all visits as defined in the Schedule of Assessments (SoA) as per protocol, including the Safety Follow-up visit and Survival Follow-up.
The Safety Follow-up period is the interval between the EOT visit and the scheduled Safety Follow-up visit, which should occur 30 days (±3 days) after the last dose of pelabresib. For patients who switch from investigational pelabresib to commercial pelabresib treatment, the Safety Follow-up period is the time from the last dose of investigational pelabresib until the first dose of commercial pelabresib. The treatment start date with commercial pelabresib will be considered the date of "early Safety Follow-up termination." All patients will be followed for AEs and SAEs for 30 days (±3 days) following the last dose of pelabresib on the extension study or until the initiation of a new anticancer therapy, whichever occurs first.
Reasonable efforts should be made to have the patient return for the Safety Follow-up visit and review any AEs that may occur during this period. If the patient cannot return to the site for the Safety Follow-up visit, then the patient should be contacted by telephone for assessment of AEs.
The end of study will occur when all parent studies have been closed with no further patients expected to be enrolled into the extension study, and all patients are either discontinued or study treatment becomes commercially available and reimbursed, or an alternate access program becomes available, whichever comes first. Prior to study completion, all patients should.have completed the Safety Follow-up visit or have been designated as lost to follow-up, died, or have withdrawn consent, whichever comes first. The sponsor reserves the right to close a study site or terminate the study at any time for any reason at the sole discretion of the sponsor.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Novartis Pharmaceuticals
- Telefonní číslo: 1-888-669-6682
- E-mail: novartis.email@novartis.com
Studijní záloha kontaktů
- Jméno: Novartis Pharmaceuticals
- Telefonní číslo: +41613241111
- E-mail: novartis.email@novartis.com
Studijní místa
-
-
-
Antwerp, Belgie, 2030
- Nábor
- Novartis Investigative Site
-
Bruges, Belgie, 8000
- Nábor
- Novartis Investigative Site
-
-
-
-
-
Amsterdam, Holandsko, 1081
- Nábor
- Novartis Investigative Site
-
-
-
-
-
Novara, Itálie, 28100
- Nábor
- Novartis Investigative Site
-
-
FI
-
Florence, FI, Itálie, 50134
- Nábor
- Novartis Investigative Site
-
-
VA
-
Varese, VA, Itálie, 21100
- Nábor
- Novartis Investigative Site
-
-
-
-
-
Cardiff, Spojené království, CF14 4XW
- Nábor
- Novartis Investigative Site
-
Glasgow, Spojené království, G12 0YN
- Nábor
- Novartis Investigative Site
-
London, Spojené království, SE1 7EH
- Nábor
- Novartis Investigative Site
-
-
-
-
California
-
Los Angeles, California, Spojené státy, 90095
- Nábor
- University of California LA
-
Vrchní vyšetřovatel:
- Gary Schiller
-
Kontakt:
- Nicole Alimi NP
- Telefonní číslo: +1 310 825 5513
- E-mail: nalimi@mednet.ucla.edu
-
-
Florida
-
Jacksonville, Florida, Spojené státy, 32224
- Nábor
- Mayo Clinic Jacksonville
-
Vrchní vyšetřovatel:
- Candido Rivera
-
Kontakt:
- Tina Kothare
- Telefonní číslo: +1 904 953 6153
- E-mail: Kothare.Tina@mayo.edu
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60611
- Nábor
- Northwestern University
-
Vrchní vyšetřovatel:
- Brady L Stein
-
Kontakt:
- Gabby Perea
- Telefonní číslo: +1 312 695 1371
- E-mail: gabrielle.perea@northwestern.edu
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- Nábor
- Uni Of Michigan Health System
-
Vrchní vyšetřovatel:
- Moshe Talpaz
-
Kontakt:
- Hayley Demchak
- E-mail: hdemchak@med.umich.edu
-
-
New York
-
New York, New York, Spojené státy, 10021
- Nábor
- New York Presbyterian Hospital
-
Vrchní vyšetřovatel:
- Joseph Scandura
-
Kontakt:
- Penina Stewart
- Telefonní číslo: +1 212 746 2932
- E-mail: pes4006@med.cornell.edu
-
New York, New York, Spojené státy, 10029-6574
- Nábor
- Mt Sinai Medical Center
-
Vrchní vyšetřovatel:
- Marina Kremyanskaya
-
Kontakt:
- Carly Sullivan
- Telefonní číslo: +1 347 714 3285
- E-mail: carly.sullivan@mssm.edu
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Able to provide signed informed consent, agreeing to all protocol and ICF requirements.
-
At least 18 years old and legally able to consent in the study's jurisdiction.
-
Previously enrolled and currently receiving pelabresib in combination with ruxolitinib or ruxolitinib alone in a parent study.
-
Demonstrating clinical benefit from pelabresib and/or ruxolitinib, as judged by the investigator.
-
Willing and able to follow all study visits, treatments, and procedures.
-
Agree to avoid pregnancy or fathering children:
- Men: Must use highly effective contraception (≥99% effective) and avoid sperm donation from eligibility check through 94 days post-treatment.
- Women of childbearing potential (WOCBP): Must test negative for pregnancy at eligibility, use highly effective contraception through 184 days post-treatment, undergo regular pregnancy testing, and avoid breastfeeding and oocyte donation during this period.
- Women not of childbearing potential (surgically sterile or postmenopausal ≥12 months without other cause) are eligible.
Note: Women with amenorrhea due to chemo/radiotherapy are considered WOCBP and must use contraception.
Additional Inclusion Criteria control (placebo + ruxolitinib) group requiring pelabresib combination treatment:
-
On a stable dose of ruxolitinib for ≥8 weeks
-
Has adequate bone marrow and organ function as defined by the following local laboratory values:
- ANC ≥ 1 × 10^9/L in the absence of growth factors for the previous 4 weeks
- Platelet count ≥ 75 × 10^9/L in the absence of growth factors or platelet transfusions during previous 4 weeks
- Peripheral blood blast count < 5%
- AST and/or ALT ≤ 2.5 × ULN of the local reference interval (≤ 5 × if the elevation can be ascribed to hepatic MF involvement, e.g., presence of hepatomegaly)
- Serum direct bilirubin < 2.0 × ULN of the local reference interval
- Calculated or measured CrCl of ≥ 45 mL/min
-
Does not have any other concurrent medical condition that in the opinion of the investigator could compromise participation in the study
Exclusion Criteria:
- Legally institutionalized or under judicial protection.
- Enrolled in another interventional clinical trial (excluding the parent study).
- History of hypersensitivity to pelabresib, its excipients, or similar drugs.
- Significant gastrointestinal issues (e.g., active IBD, unresolved nausea/vomiting/diarrhea > Grade 1) that may affect drug absorption.
- Any medical condition deemed unsuitable by the investigator.
- Uncontrolled illness or condition that may compromise safety or protocol compliance.
- Received systemic anticancer or investigational treatment (excluding parent study drug or hormonal therapy) within 2 weeks or 5 half-lives before first dose. (Hydroxyurea/anagrelide allowed up to 24 hours prior.)
- Received hematopoietic growth factors or androgenic steroids within 4 weeks before first dose.
- Used strong CYP3A4 inhibitors/inducers (e.g., St. John's wort) within 2 weeks before first dose. Use during treatment is prohibited.
- Received immunosuppressive agents with systemic activity (>10 mg QD prednisone or equivalent) less than 4 weeks before the first dose of study drug in the extension study. Participants who received topical, nasal, intra-articular, inhaled, and other forms of corticosteroids without systemic activity are eligible
- Received a live vaccination within 30 days prior to the first dose of study drug in the extension study, except for COVID-19 vaccination
- Female participants who are pregnant, breastfeeding, or not using required contraception.
- Male participants who do not agree to use contraception or refrain from sperm donation as specified.
- Unwilling or unable to comply with the study protocol.
Additional Exclusion Criterion for participants receiving ruxolitinib only treatment
• Local access to commercially available and reimbursed ruxolitinib.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Pelabresib and/or ruxolitinib
Participants who have previously received pelabresib alone or pelabresib in combination with ruxolitinib or ruxolitinib alone will continue to receive the same regimen as administered in the parent study. Additionally, the MANIFEST-2 (NCT04603495) control group (i.e., treated with placebo + ruxolitinib) patients, will be offered pelabresib combination treatment at the time of enrollment if the investigator sees any potential benefit of adding pelabresib to ruxolitinib. |
Small molecule inhibitor of bromodomain and extraterminal (BET) protein
Ostatní jména:
Small molecule selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Treatment-emergent adverse events (TEAEs) and serious TEAEs
Časové okno: 5 years
|
To evaluate long-term safety in patients who are receiving pelabresib |
5 years
|
|
Survival Follow-up
Časové okno: 5 years
|
Survival Follow-up consists of Survival and Leukemia-Free Survival Follow-up. All participants in the extension study will be followed up for Survival, while participants with hematological malignancies will be followed up for Survival and Leukemia-Free Survival. |
5 years
|
|
Duration of Response (DoR)
Časové okno: 5 years
|
DOR defined as the time from the date of first response to the date of confirmed disease progression |
5 years
|
|
Progression-free survival (PFS)
Časové okno: 5 years
|
PFS defined as the time from first dose to confirmed disease progression or death, whichever occurs first. |
5 years
|
|
Leukemia-free survival (LFS)
Časové okno: 5 years
|
LFS defined as the time from first dose to the date of leukemic transformation or death, whichever occurs first. |
5 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- CDAK539A12001B
- CNST0610C210 (Jiný identifikátor: Constellation Pharmaceuticals)
- 2023-508950-24-00 (Identifikátor registru: EU CT Number)
- 2023 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .